Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets

Su-Jin Park, Kwang-Min Yu, Young-Il Kim, Se-Mi Kim, Eun-Ha Kim, Seong-Gyu Kim, Eun Ji Kim, Mark Anthony B Casel, Rare Rollon, Seung-Gyu Jang, Min-Hyeok Lee, Jae-Hyung Chang, Min-Suk Song, Hye Won Jeong, Younho Choi, Weiqiang Chen, Woo-Jin Shin, Jae U Jung, Young Ki Choi, Su-Jin Park, Kwang-Min Yu, Young-Il Kim, Se-Mi Kim, Eun-Ha Kim, Seong-Gyu Kim, Eun Ji Kim, Mark Anthony B Casel, Rare Rollon, Seung-Gyu Jang, Min-Hyeok Lee, Jae-Hyung Chang, Min-Suk Song, Hye Won Jeong, Younho Choi, Weiqiang Chen, Woo-Jin Shin, Jae U Jung, Young Ki Choi

Abstract

Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral candidates for human trials. To this end, the antiviral efficacies of lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir for SARS-CoV-2 infection were assessed in the ferret infection model. While the lopinavir-ritonavir-, hydroxychloroquine sulfate-, or emtricitabine-tenofovir-treated group exhibited lower overall clinical scores than the phosphate-buffered saline (PBS)-treated control group, the virus titers in nasal washes, stool specimens, and respiratory tissues were similar between all three antiviral-candidate-treated groups and the PBS-treated control group. Only the emtricitabine-tenofovir-treated group showed lower virus titers in nasal washes at 8 days postinfection (dpi) than the PBS-treated control group. To further explore the effect of immune suppression on viral infection and clinical outcome, ferrets were treated with azathioprine, an immunosuppressive drug. Compared to the PBS-treated control group, azathioprine-immunosuppressed ferrets exhibited a longer period of clinical illness, higher virus titers in nasal turbinate, delayed virus clearance, and significantly lower serum neutralization (SN) antibody titers. Taken together, all antiviral drugs tested marginally reduced the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers. Despite the potential discrepancy of drug efficacies between animals and humans, these preclinical ferret data should be highly informative to future therapeutic treatment of COVID-19 patients.IMPORTANCE The SARS-CoV-2 pandemic continues to spread worldwide, with rapidly increasing numbers of mortalities, placing increasing strain on health care systems. Despite serious public health concerns, no effective vaccines or therapeutics have been approved by regulatory agencies. In this study, we tested the FDA-approved drugs lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir against SARS-CoV-2 infection in a highly susceptible ferret infection model. While most of the drug treatments marginally reduced clinical symptoms, they did not reduce virus titers, with the exception of emtricitabine-tenofovir treatment, which led to diminished virus titers in nasal washes at 8 dpi. Further, the azathioprine-treated immunosuppressed ferrets showed delayed virus clearance and low SN titers, resulting in a prolonged infection. As several FDA-approved or repurposed drugs are being tested as antiviral candidates at clinics without sufficient information, rapid preclinical animal studies should proceed to identify therapeutic drug candidates with strong antiviral potential and high safety prior to a human efficacy trial.

Keywords: COVID-19; antiviral therapeutics; ferrets; immunosuppression; serum neutralization; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Copyright © 2020 Park et al.

Figures

FIG 1
FIG 1
Schedule of drug treatments and SARS-CoV-2 infection in ferrets. To induce the immunosuppression condition, PBS or azathioprine was orally administered to ferrets for the entire experimental period. All groups of ferrets were administered each drug or PBS via oral gavage once, starting at 1 dpi.
FIG 2
FIG 2
Clinical features of drug-treated ferret groups. Ten ferrets per group were inoculated via the i.n. route with 105.8 TCID50 of the NMC-nCoV02 strain. Starting at 1 day of postinfection, lopinavir-ritonavir, hydroxychloroquine sulfate, emtricitabine-tenofovir, or azathioprine was orally administered to each group. Temperature changes (A) and relative weight changes (B) are shown with standard errors of the means. (A) Temperature is represented as relative change (degrees Celsius), and (B) weight change is demonstrated as a percentage of the initial body weight. Nasal wash and fecal samples were collected at 2, 4, 6, 8, 10, 12, and 14 dpi from nasal wash specimens and fecal swabs. (C) Virus titers (TCID50) were measured in nasal wash specimens from each group. (D) The number of viral RNA copies was measured in fecal samples using qRT-PCR. Viral titers and RNA copy numbers are shown as means ± standard errors of the means (SEM) from four animals, and titers below the limit of detection are shown as 1 log10 TCID50/ml or 0.3 log10 viral RNA copy numbers/ml (dashed lines). Asterisks indicate statistical significance between the control and each group as determined by two-way ANOVA and subsequent Dunnett’s test (*, P < 0.05).
FIG 3
FIG 3
Virus titers in respiratory tissues. Groups of ferrets (3/group) were sacrificed at 4 and 8 dpi. Viral titers were measured in turbinate (A) and lung (B) by determining the numbers of TCID50 per gram. The limit of detection is 1 log10 TCID50/g and indicated by the dotted line for each representation.
FIG 4
FIG 4
Comparison of serum neutralization antibody titers of drug-treated ferrets. Blood was collected at 10, 14, and 21 dpi from each group of ferrets (n = 4), and serum neutralization antibody titers were measured in Vero cells. The serum neutralization titer of each ferret is represented by an individual dot in each bar graph. Asterisks indicate statistical significance between the control and each group, as determined by two-way ANOVA and subsequent Dunnett’s test (*, P < 0.05; ***, P < 0.001).

References

    1. WHO. 2020. Coronavirus disease 2019 (COVID-19) situation report 88. WHO, Geneva, Switzerland: . Accessed 17 April 2020.
    1. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 11 Marc H 2020. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA doi:10.1001/jama.2020.3786.
    1. Pan Y, Zhang D, Yang P, Poon LL, Wang Q. 2020. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 20:411–412. doi:10.1016/S1473-3099(20)30113-4.
    1. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-C, Chik TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon RW-S, Luo C-T, Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20:565–574. doi:10.1016/S1473-3099(20)30196-1.
    1. Choy K-T, Wong AY-L, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP-H, Huang X, Peiris M, Yen H-L. 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 178:104786. doi:10.1016/j.antiviral.2020.104786.
    1. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. 2014. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:4875–4884. doi:10.1128/AAC.03011-14.
    1. Chan JF-W, Yao Y, Yeung M-L, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai J-P, Chu H, Zhou J, Chen H, Qin C, Yuen K-Y. 2015. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904–1913. doi:10.1093/infdis/jiv392.
    1. Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. 2016. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α of Middle East respiratory syndrome. Antivir Ther 21:455–459. doi:10.3851/IMP3002.
    1. Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, Koulouris NG, Osterhaus AD, Koopmans MP, Tsakris A. 2014. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 44:528–532. doi:10.1016/j.ijantimicag.2014.07.026.
    1. Gostner JM, Schröcksnadel S, Becker K, Jenny M, Schennach H, Uberall F, Fuchs D. 2012. Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. FEBS Open Bio 2:241–245. doi:10.1016/j.fob.2012.08.004.
    1. Liu K, Tang M, Liu Q, Han X, Jin H, Zhu H, Li Y, He L, Ji H, Zhou B. 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. doi:10.1038/s41421-020-0156-0.
    1. Helfgott DC. 8 April 2020. Hydroxychloroquine for SARS-CoV-2 infection: how did we get here? Infect Dis Advisor . Accessed 21 April 2020.
    1. Brindley E. 7 April 2020. Connecticut hospitals using anti-malaria drug chloroquine ‘out of desperation’ to treat COVID-19. Hartford Courant, Hartford, CT: .
    1. McChesney EW. 1983. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 75:11–18. doi:10.1016/0002-9343(83)91265-2.
    1. Danza Á, Grana D, Goni M, Vargas A, Ruiz-Irastorza G. 2016. Hydroxychloroquine for autoimmune diseases. Rev Med Chil 144:232–240. (In Spanish.) doi:10.4067/S0034-98872016000200012.
    1. Lou L. 2013. Advances in nucleotide antiviral development from scientific discovery to clinical applications: tenofovir disoproxil fumarate for hepatitis B. J Clin Transl Hepatol 1:33–38. doi:10.14218/JCTH.2013.004XX.
    1. De Clercq E. 2016. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol 119:1–7. doi:10.1016/j.bcp.2016.04.015.
    1. Kim Y-I, Kim S-G, Kim S-M, Kim E-H, Park S-J, Yu K-M, Chang J-H, Kim EJ, Lee S, Casel MAB, Um J, Song M-S, Jeong HW, Lai VD, Kim Y, Chin BS, Park J-S, Chung K-H, Foo S-S, Poo H, Mo I-P, Lee O-J, Webby RJ, Jung JU, Choi YK. 5 April 2020. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe doi:10.1016/j.chom.2020.03.023.
    1. Leung WK, To K-f, Chan PK, Chan HL, Wu AK, Lee N, Yuen KY, Sung JJ. 2003. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125:1011–1017. doi:10.1016/s0016-5085(03)01215-0.
    1. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z. 8 April 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science doi:10.1126/science.abb7015.
    1. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wölfel R, Hoelscher M. 2020. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382:970–971. doi:10.1056/NEJMc2001468.
    1. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S, Tsoi H-W, Lo SK-F, Chan K-H, Poon VK-M, Chan W-M, Ip JD, Cai J-P, Cheng VC-C, Chen H, Hui CK-M, Yuen K-Y. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:514–523. doi:10.1016/S0140-6736(20)30154-9.
    1. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv doi:10.1101/2020.03.30.20047365.
    1. Prada N, Brandi Davis P-P, La Roche M, Duh F-M, Carrington M, Poles M, Mehandru S, Mohri H, Markowitz M. 2008. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr 49:117–122. doi:10.1097/QAI.0b013e3181869a9b.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться